Both WHO-HAEM5 and ICC have recognized SF3B1 mutation and bi-allelic TP53 mutation as defining new MDS subtypes, while retaining isolated del(5q) as a specific MDS subtype. This evidence concerns the gene SF3B1 and intrahepatic cholangiocarcinoma.